Eli Lilly has introduced a new, more affordable form of its weight loss drug, Zepbound, offering single-dose vials at nearly half the usual price. The move makes the medication more accessible to uninsured and Medicare patients. It also aims to expand the drug's supply in response to rising demand and combat the spread of counterfeit versions. The vials are available directly through Lilly's website, offering a transparent pricing model by bypassing third-party supply chains. This initiative also seeks to ensure patients receive genuine, FDA-approved treatments.
